Refractory
diseases are those diseases that did not respond to the treatment as has
surfaced again. Relapsed chronic lymphocytic leukaemia means that the cancer
did not respond to the treatment and has recurred reaching remission. Treatment
for this will include chemotherapy based on its response the first time. If the
disease becomes resistant to chemotherapy, other drugs are used to treat
leukemia. Other treatment options include targeted therapy, surgery, radiation
therapy and supportive therapy.
Clinical
trials are conducted in medical research labs to find better ways to prevent
and treat diseases or diagnose them. They give solutions on the medical
approaches suitable for certain illness to a certain group of people
specifically. These trials help a great deal in making healthcare decisions.
Since they answer scientific questions, these trials are required to be carried
on under strict and scientific standards that protect the interests of the
patients. They are also the final and the most important stage of clinical
research and development. Clinical trials for drugs take place in four phases-
first, they test an experimental drug on a few people and study the effects;
second, they test the drug on more people than in Phase 1 which may extend up
to years; third, they include many other participants to test for safety and
efficacy and study the side effects deeper than in Phase 2; fourth, getting
approval of the usage of drug from the relevant authority.
Ken
Research’s Refractory
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018
gives an overview of the global clinical trials landscape and top-level data
related to clinical trials by Regio, Country (G7 and E7), Trial Status, trial
Phase, Sponsor type and End point status. The report reviews top companies
involved and enlists all trials (Trial title, Phase, and Status) pertaining to
the company and all the unaccomplished trials (Terminated, Suspended and
Withdrawn) with reason for their non-accomplishments. It provides enrolment
trends for the past five years and the latest news relating to these trials for
the past three months. The companies involved in the clinical trials of
Refractory Chronic Lymphocytic Leukemia are AbbVie Inc, F. Hoffmann-La Roche
Ltd, Celgene Corp, Novartis AG, Johnson & Johnson, AstraZeneca Plc, Gilead
Sciences Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb Co and Sanofi. The
report will enhance the decision- making capabilities and helps to create an
effective counter strategy to gain competitive advantage.
For more information, click on the
link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/refractory-chronic-lymphocytic/154882-91.html
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249